グラクソ・スミスクライン

 GSKのチャート


 GSKの企業情報

symbol GSK
会社名 GlaxoSmithKline Plc (グラクソ・スミスクライン)
分野(sector)   
産業(industry)   
業種 医薬品   医療関連(Health Care)
概要 グラクソ・スミスクライン(GlaxoSmithKline plc)は医療グループであり、ワクチン、市販薬(OTC)及び健康製品等の医薬品の作成、発見、開発、製造及び販売に従事する。同社は主に呼吸器、抗ウイルス、中枢神経系、心血管と泌尿生殖器、代謝、抗菌、腫瘍と嘔吐、皮膚、希少疾患、免疫・炎症、ワクチン及びヒト免疫不全ウイルス(HIV)等の治療分野向けに医薬品を提供している。同社は主に医薬品事業、ワクチン事業、およびコンシューマーヘルスケア事業の3事業区分により構成される。平成24年1月31日、同社は米国とカナダにおけるブランドをPrestige Brands Holdingsに売却完了した。同年8月、同社はHuman Genome Sciencesを買収した。平成25年1月30日、GSKは同社における持ち分の29.3%を追加買収した。  グラクソ・スミスクラインはイギリスの製薬メ―カ―。呼吸器、抗ウイルス、中枢神経、心臓血管、泌尿生殖器、がん、ワクチン、HIV分野で医療用医薬品を展開。主要製品は、鼻炎治療薬、肺疾患治療薬、抗血栓症薬、がん治療薬、抗HIV薬、ジフテリア・インフルエンザワクチンなど。オ―ラルケア製品、禁煙補助薬、市販薬、栄養補助製品などヘルスケア製品も提供。  
本社所在地 980 Great West Road Brentford Middlesex TW8 9GS GBR
代表者氏名 Emma Walmsley
代表者役職名 Chief Executive Officer Executive Director
電話番号 +44 20-8047-5000
設立年月日 36495
市場名 NYSE(ニューヨーク証券取引所)
ipoyear
従業員数 95490人
url www.gsk.com
nasdaq_url
adr_tso
EBITDA (百万ドル) 12929.04000
終値(lastsale)
時価総額(marketcap)
時価総額 (百万ドル) 103966.30000
売上高 (百万ドル) 40178.07000
企業価値(EV) (百万ドル) 132783.55500
当期純利益 (百万ドル) 4885.87000
決算概要 BRIEF: For the fiscal year ended 31 December 2018 GlaxoSmithKline plc (ADR) revenues increased 2% to £30.82B. Net income before extraordinary items increased 44% to £3.75B. Revenues reflect Vaccines segment increase of 14% to £5.89B US segment increase of 6% to £11.98B. Net income benefited from Consumer Healthcare segment income increase from £1.37B to £5.74B Unallocated segment loss decrease of 23% to £3.72B. Dividend per share remained flat at £0.80.

 GSKのテクニカル分析


 GSKのニュース

   Addiction Treatment Market Report 2021-2028 | Size, Share, Growth, Trends, Competitive Landscape, Revenue, Forecast Analysis  2021/10/07 11:05:00 Intrado Digital Media
Top Players Covered in the Addiction Treatment Market Research Report Are Cipla Inc., Allergan, Alkermes, Pfizer Inc., Orexo AB, GlaxoSmithKline plc., Sandoz International GmbH, Reckitt Benckiser Group plc., Teva Pharmaceutical Industries Ltd., Novartis AG, Indivior PLC. and other key market players. Top Players Covered in the Addiction Treatment Market Research Report Are Cipla Inc., Allergan, Alkermes, Pfizer Inc., Orexo AB, GlaxoSmithKline plc., Sandoz International GmbH, Reckitt Benckiser Group plc., Teva Pharmaceutical Industries Ltd., Novartis AG, Indivior PLC. and other key market players.
   Global Paracetamol Market (2021 to 2026) - Growth, Trends, COVID-19 Impact and Forecasts - ResearchAndMarkets.com  2021/10/07 10:37:00 Business Wire
DUBLIN--(BUSINESS WIRE)--The "Paracetamol Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)" report has been added to ResearchAndMarkets.com''s offering. The Paracetamol Market is poised to grow at a CAGR of 4.3% during the forecast period (2021-2026). Companies Mentioned GlaxoSmithKline plc Mallinckrodt Pharmaceuticals Sanofi Sun Pharmaceuticals Industries ltd Teva Pharmaceuticals USA, Inc Dr. Reddy''s Laboratories Biological E CFL Pharma Cipla Genesis Biotec Inc. Key Market
   WHO approves worlds first malaria vaccine for African children  2021/10/07 06:16:40 Chronicle NG
The World Health Organization (WHO) said on Wednesday the only approved vaccine against malaria should be widely given to African children, potentially marking a major advance against a disease that kills hundreds of thousands of people annually. The WHO recommendation is for RTS,S or Mosquirix a vaccine developed by British drugmaker GlaxoSmithKline. Since []
   WHO recommends broad use of worlds 1st malaria vaccine  2021/10/07 00:40:56 Buziness Bytes
Geneva, Oct 7 (IANS) The World Health Organization (WHO) said on Wednesday that it has recommended widespread use of the worlds first malaria vaccine called RTS,S/AS01 (RTS,S) for children in sub-Saharan Africa. According to the WHO, the vaccine is the result of 30 years of research and development by British pharmaceutical company GlaxoSmithKline (GSK) in [] The post WHO recommends broad use of worlds 1st malaria vaccine appeared first on Buziness Bytes .
   Historic moment: UN endorses first vaccine for malaria  2021/10/06 19:58:32 Mercury News
The vaccine, known as Mosquirix, was developed by GlaxoSmithKline in 1987. While it''s the first to be authorized, it does face challenges: The vaccine is only about 30% effective, it requires up to four doses, and its protection fades after several months.
   Global Anti Obesity Drugs Market Growth Analysis, Latest Trends and Forecast till 2027| Pfizer, Merck, Roche, GlaxoSmithKline  2021/09/09 12:56:02 OpenPR
The worrying growth in obesity prevalence, particularly in the industrialized regions of North America, has been driving the anti-obesity medicine market by itself. Anti-obesity medications, both prescription and over-the-counter, are divided into two categories: centrally acting and peripherally acting. These
   Statistics 2021 Report on Seasonal Influenza Vaccine Market Size & Sales Likely to Grow Over USD 9,801.8 Mn by 2030: Facts & Factors  2021/09/09 12:27:11 Benzinga
New York, NY, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Facts and Factors have published a new research report titled "Seasonal Influenza Vaccine Market By Product Type (Quadrivalent, and Trivalent), By Sector (Public, and Private), End-User / Sales Channel (Hospitals, Government Suppliers, and Others): Global & Regional Industry Perspective, Comprehensive Analysis, Historical Trends, and Forecasts, 2021 2030" . "According to the recent research report, the demand of global Seasonal Influenza Vaccine Market size & share expected to reach to USD 9,801.8 Million by 2030 from USD 5,638.3 Million in 2020, at a compound annual growth rate (CAGR) of 5.6% during the forecast period 2021 to 2030" Global Seasonal Influenza Vaccine Market: Overview Influenza (also terms as "flu") is one of the serious diseases that can lead to hospitalization and even death. Influenza vaccines are widely used in order to protect an individual against infection by influenza viruses which are also known as flu shots or flu jabs.
   Goldseek Announces 0.07% Copper over 43.5m in Historical Reassaying at Beschefer Project  2021/09/09 11:30:00 The North America Newswire
Highlights: - Assay results on historical drilling (BE12-010) returned 0.04% Cu over 106.5m, including: - 0.09% Cu over 18m - 0.07% Cu over 43.5m - Low-grade copper discovery adds base metal potential to a gold system currently being drilled with a 5.000m program - The presence of higher-grade copper in historical drilling (2.30% Cu over 2.58m in BE11-002) supports the potential for economic intercepts amongst this system September 9, 2021 - TheNewswire - London, Ontario - Goldseek Resources Inc. ( C NSX :GSK. CN ) (FSE:4KG) (OTC:GSKKF) (Goldseek or the Company ) is pleased to announce results from 500 meters of historical drilling previously unsampled at the Beschefer Project. The Company was successful in identifying base metal potential through the identification of large intercepts of low-grade copper. The Beschefer Project is located approximately 30 kilometers southwest of Wallbridges Fenelon Gold Project. On March 3rd, 2021, the Company entered into an option agreement on the Beschefer Project to earn 100% over 4 years from Wallbridge Mining Company Limited (see news release dated March 3, 2021) (Wallbridge).
   Massive growth on Conjugate Vaccines Market During 2021-2027 | GlaxoSmithKline, Serum Institute, Johnson & Johnson  2021/09/09 11:28:43 OpenPR
Conjugate Vaccines Market size is anticipated to reach 12.50% CAGR during the forecast period 2021-2027. The increasing interest of the individuals in this industry is that the major reason for the expansion of this market. A conjugate vaccine is a type
   Global Invasive Candidiasis Market Scope Report Forecast to 2021-27 |key players are Novartis Ag, Sanofi-Aventis, Pfizer, Inc., MerckCo., Inc., Enzon Pharmaceuticals Inc., Bayer Ag, Astellas Pharma, Inc., Glaxosmithkline Plc, Abbott,Cipla & Others  2021/09/09 09:53:15 OpenPR
Infinity Business Insights presents a report on Invasive Candidiasis Market. As we are aware about the Candidiasis which is an infection caused by the yeast candida, which is also known as fungus and is found in the human
   'Halftime Report' Traders Weigh In On GlaxoSmithKline, Snowflake And More  2021/06/03 20:13:05 Benzinga
On CNBC's "Fast Money Halftime Report," Jenny Harrington said GlaxoSmithKline plc (NYSE: GSK ) has performed terribly, but we could be at a beginning of value creation and value being unlocked as the company is spinning off its health care … Full story available on Benzinga.com
   Biden lays out plan to share 25 million COVID-19 vaccine doses with the world  2021/06/03 19:25:59 AOL
WASHINGTON (Reuters) -The White House on Thursday laid out a plan for the United States to share 25 million surplus COVID-19 vaccine doses with the world and said it would lift some restrictions to allow other countries to buy U.S.-made supplies for vaccine production more easily. President Joe Biden said the United States would share the vaccines without expectation of political favors in return. Biden has pledged to share some 80 million COVID-19 vaccines internationally this month. The United States will donate nearly 19 million doses through the COVAX international vaccine sharing program, he said in a statement. Through COVAX, some 6 million doses would go to Latin America and the Caribbean, about 7 million doses to South and Southeast Asia and roughly 5 million to Africa. The remaining doses, amounting to just over 6 million, would go directly from the United States to countries including Canada, Mexico, India and South Korea, he said. "We are sharing these doses not to secure favors or extract concessions," Biden said in a statement. "We are sharing these vaccines to save lives and to lead the world in bringing an end to the pandemic, with the power of our example and with our values." Although the United States is working through the COVAX facility co-run by the World Health Organization, the White House retains final say in which countries receive U.S. doses and how many, said national security adviser Jake Sullivan.
   GSK defeats 425 lawsuits alleging Zofran causes birth defects  2021/06/01 20:47:00 Reuters
GlaxoSmithKline Plc on Tuesday defeated lawsuits by 425 women alleging it failed to warn that taking the anti-nausea drug Zofran during pregnancy could cause birth defects, after a judge ruled their state-law claims were preempted by federal law.
   Activist Hedge Fund Elliott Questions GSK CEO Walmsley's Leadership: Mail on Sunday  2021/06/01 18:09:35 Benzinga
GlaxoSmithKline Plc (NYSE: GSK ) appeared to dodge a potential shakeup last week when Elliott Management said it would not push the sale of its vaccines and pharmaceuticals business or push to slash R&D spending. But now, the activist firm is reportedly raising questions about the company's CEO Emma Walmsley. In private talks with Glaxo shareholders, Elliott has questioned … Full story available on Benzinga.com
   A Look Into GlaxoSmithKline's Price Over Earnings  2021/06/01 10:10:00 Benzinga
Right now, GlaxoSmithKline Inc. (NYSE:GSK) share price is at $38.53, after a 0.62% drop. Over the past month, the stock spiked by 2.75%, but …

 関連キーワード  (医薬品 米国株 グラクソ・スミスクライン GSK )

 twitter  (公式ツイッターやCEOツイッターなど)

GSK動画